Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9774407 | 0.81 | LPL (0.43) | L3MBTL1HPGDTP53LPLLIPG | |
| SCHEMBL1415320 | 0.81 | ESR1 (0.38) | TDP1TAAR1LMNAESR1ESR2 | |
| SCHEMBL18242410 | 0.80 | L3MBTL1 (0.52) | TSHRMAPK1ATMTDP1L3MBTL1 | |
| SCHEMBL139408 | 0.79 | L3MBTL1 (0.56) | TSHRMAPK1ATMTDP1L3MBTL1 | |
| SCHEMBL500563 | 0.79 | TSHR (0.56) | TSHRMAPK1ATMTDP1L3MBTL1 | |
| SCHEMBL9596827 | 0.78 | PTGS1 (0.53) | TSHRAKR1C3AKR1C2LMNAESR1 | |
| SCHEMBL6448218 | 0.78 | PTGS1 (0.53) | TSHRAKR1C3AKR1C2LMNAESR1 | |
| SCHEMBL11726229 | 0.78 | FAAH (0.36) | TSHRMAPK1ATMTDP1L3MBTL1 | |
| SCHEMBL9596832 | 0.78 | PTGS1 (0.53) | TSHRAKR1C3AKR1C2LMNAESR1 | |
| SCHEMBL9030475 | 0.78 | HTR2A (0.54) | TSHRTP53LPLLIPGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117702142-A | C (C) 4 Process for preparing substituted pyridine derivatives | 五邑大学 | 2024-03-15 | — | — | CN | disclosed |
| CN-105473575-A | Benzimidazolyl-methylurea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD | 2016-04-06 | — | — | CN | disclosed |
| CN-101506203-B | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other syndromes | NOVARTIS AG | 2013-10-16 | — | — | CN | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101506203-A | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and o | NOVARTIS AG (CH) | 2009-08-12 | — | — | CN | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| CN-1329481-C | Liquid crystal compound containing monofluoro ethylene bridge and its preparing method | UNIV TSINGHUA (CN) | 2007-08-01 | — | — | CN | disclosed |
| CN-1743414-A | Liquid crystal compound containing monofluoro ethylene bridge and its preparing method | UNIV TSINGHUA (CN) | 2006-03-08 | — | — | CN | disclosed |
| US-5026729-A | Lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1991-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | TSHR 222/4885MAPK1 3544/4885ATM 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.